Skip to content
DataLookout
Menu

NCT03972657

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 26 versions: 26 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 24 → 27 locations
  2. Notable Eligibility criteria expanded, about 17 words
    • Primary endpoints: details revised at 1 of 9 entries
    • Study sites: 24 to 26
    • Secondary endpoints: details revised at 1 of 12 entries
  3. Minor Study sites: 22 to 24v24
  4. Minor Study sites: 21 to 22v23
  5. Minor Study sites: 17 to 21v22
Show 20 earlier versionsHide 20 earlier versions
  1. Notable Primary and study completion dates pushed to Nov 15, 2027v21 Show 4 more changesShow less
    • Primary endpoints revised (9)
    • Eligibility criteria expanded, about 1 word
    • Secondary endpoints revised (12)
    • Study title expanded, about 1 word
  2. Minor Study sites: 16 to 17v20
  3. Minor Study sites: 15 to 16v19
  4. Minor Study sites: 14 to 15v18
  5. Notable Eligibility criteria shortened, about 4 wordsv17 Show 6 more changesShow less
    • Enrollment target: 297 to 345
    • Study sites: 13 to 14
    • Interventions: Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug) to Cemiplimab (Drug), REGN5678 (Drug)
    • Secondary endpoints: 11 to 12
    • Study title expanded, about 12 words
    • Study arms: 3 to 4
  6. Notable Primary completion date: Feb 13, 2024 to Aug 1, 2025v16 Show 8 more changesShow less
    • Eligibility criteria expanded, about 130 words
    • Primary endpoints: 8 to 9
    • Enrollment target: 216 to 297
    • Study completion date: Feb 19, 2025 to Jul 3, 2026
    • Interventions: 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug) to Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug)
    • Secondary endpoints revised (11)
    • Study arms: 2 to 3
    • Study title expanded, about 5 words
  7. Minor Study sites: 12 to 13v15
  8. Minor Study sites: 11 to 12v14
  9. Minor Site details revised at 1 of 11 sitesv13
  10. Notable Enrollment target: 129 to 216v12 Show 4 more changesShow less
    • Primary completion date: Jun 28, 2023 to Feb 13, 2024
    • Study completion date: Jul 16, 2024 to Feb 19, 2025
    • Interventions: 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug) to 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug), Sarilumab (Drug)
    • Primary endpoints revised (8)
  11. Minor Study sites: 10 to 11v11
  12. Minor Study sites: 9 to 10v10
  13. Minor Study sites: 8 to 9v9
  14. Minor Study sites: 7 to 8v8
  15. Minor Study sites: 6 to 7v7
  16. Minor Primary completion date: Jun 16, 2024 to Jun 28, 2023
    • Study completion date: Jun 16, 2024 to Jul 16, 2024
    • Secondary endpoints: 12 to 11
    • Site details revised at 1 of 6 sites
    v6
  17. Notable Primary and study completion dates: Sep 2, 2025 to Jun 16, 2024
    • Eligibility criteria shortened, about 20 words
    • Enrollment target: 123 to 129
    v5
  18. Notable Primary and study completion dates: Oct 30, 2024 to Sep 2, 2025
    • Eligibility criteria expanded, about 55 words
    • Interventions: Cemiplimab (Drug), REGN5678 (Drug) to 18F-DCFPyL (Other), Cemiplimab (Drug), REGN5678 (Drug)
    v4
  19. Notable Start date: Jun 26, 2019 to Aug 12, 2019
    • Study sites: 1 to 6
    v3
  20. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: Jul 10, 2024 to Oct 30, 2024
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Through study completion, up to 5 years
Incidence and severity of Adverse Event of Special Interests (AESIs)
Timeframe: Through study completion, up to 5 years
Incidence and severity of Serious Adverse Events (SAEs)
Timeframe: Through study completion, up to 5 years
Number of participants with Grade ≥3 laboratory abnormalities
Timeframe: Through study completion, up to 5 years
Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: First dose through day 42 of last participant in each dose level
Concentration of REGN5678 in serum over time
Timeframe: Through study completion, up to 5 years
Concentration of REGN5678 in combination with cemiplimab in serum over time
Timeframe: Through study completion, up to 5 years
Composite Response Rate (CRR) of 50% decline of Prostate Specific Antigen (PSA) and/or confirmed radiographic response of complete (CR) or partial response (PR)
Timeframe: Through study completion, up to 5 years
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Timeframe: Through study completion, up to 5 years

Secondary (12)

CRR of 50% decline of PSA and/or confirmed radiographic of CR or PR
ORR per RECIST 1.1 criteria
Incidence and severity of TEAEs
Incidence and severity of AESIs
Incidence and severity of SAEs
Show 7 moreShow less
Number of participants with grade ≥3 laboratory abnormalities
Concentration of REGN5678 in serum over time
Concentration of REGN5678 in combination with cemiplimab in serum over time
Percentage of participants with ≥50% decline of PSA
Percentage of participants with ≥90% decline of PSA
Presence or absence of antibodies against REGN5678
Presence or absence of antibodies against cemiplimab

Arms and interventions

mCRPC - dose escalation cohortExperimental

REGN5678 with or without cemiplimab

mCRPC - dose expansion cohortExperimental

REGN5678 with or without cemiplimab

ccRCC - dose escalation cohortExperimental

REGN5678 with or without cemiplimab

ccRCC - dose expansion cohortExperimental

REGN5678 with or without cemiplimab

Drugs: REGN5678, Cemiplimab

Sites

27 sites in 2 countries

United States 24, South Korea 3